TIGITは体内での活性を調節することで作用する薬剤の標的として登場した最新の免疫チェックポイント阻害剤の 1 つです。アンタゴニストとアゴニストの両方が TIGIT に対して開発されており、前者が優勢であり、主にさまざまな種類のヒトの病気に使用されています。TIGIT阻害剤は、さまざまながんに対して広く試験されている免疫チェックポイント阻害剤と同様の傾向をたどっているようであり、現在、これらの新規阻害剤が同等の阻害剤で示された治療上の成功を再現できるかどうかを評価するために、いくつかの前臨床および臨床研究が実施されています。これらの TIGIT 阻害剤の一部は現在、規制当局の承認に近づいており、これが TIGIT 標的薬の開発の主要な推進要因であると考えられています。
目次
1. Introduction to Anti TIGIT Antibody
1.1 Overview
1.2 Mechanism of Anti TIGIT Antibodies
1.3 Clinical Approaches to Target TIGIT
2. Role of Anti TIGIT Antibody by Indication
2.1 Cancer
2.2 Viral Infections
2.3 Autoimmune Disorders
3. TIGIT Co Inhibition with PD1 or PDL1
4. Global Anti TIGIT Antibodies Clinical Trials Overview
4.1 By Company
4.2 By Country
4.3 By Indication
4.4 By Patient Segment
4.5 By Phase
5. Global Anti TIGIT Antibodies Clinical Pipeline By Company, Indication and Phase
5.1 Research
5.2 Preclinical
5.3 Phase-I
5.4 Phase-I/II
5.5 Phase-II
5.6 Phase-III
6. Global Anti TIGIT Antibodies Market Dynamics
6.1 Market Drivers
6.2 Commercialization Challenges
7. Global Anti TIGIT Antibodies Market Future Outlook
8. Competitive Landscape
8.1 Akeso Biopharma
8.2 BeiGene
8.3 Bio-Thera Solutions
8.4 Biotheus
8.5 Compugen
8.6 FutureGen Biopharmaceutical
8.7 Merck Sharp and Dohme
8.8 Nanjing Sanhome Pharmaceutical
8.9 OriCell Therapeutics
8.10 Phio Pharmaceuticals
8.11 Roche
8.12 Shanghai Henlius Biotech
8.13 Shanghai Junshi Biosciences
8.14 Simcere Pharmaceutical Group
8.15 Tasrif Pharmaceutical
List of Figures & Tables
Figure 1-1: TIGIT/DNAX Accessory Molecule-1 Pathway
Figure 1-2: TIGIT Inhibitor - Proposed Mechanism of Action
Figure 1-3: TIGIT Inhibitor - Mechanism of Action
Figure 1-4: Binding Efficacy of Monoclonal Antibody
Figure 1-5: Binding Efficacy of Bispecific Antibodies
Figure 1-6: Advantages of Small Molecule Drugs over Therapeutic Antibodies
Figure 2-1: Enhanced Anti-Tumor Effects of Dual TIGIT and PD-1 Blockade
Figure 2-2: Blockade of TIGIT on Tregs Reduces Their Immunosuppressive Functions
Figure 2-3: Blockade of TIGIT on NK Cells Augments Anti-Tumor Immunity
Figure 2-4: Hypothetical Outcomes of Using TIGIT Blockade for HIV-1 Therapy
Figure 2-5: TIGIT Associated Autoimmune Disorders
Figure 4-1: Global - Anti TIGIT Antibodies Clinical Trials by Company (Number of Drugs), 2023 - 2024
Figure 4-2: Global - Anti TIGIT Antibodies Clinical Trials by Country (Number of Drugs), 2023 - 2024
Figure 4-3: Global - Anti TIGIT Antibodies Clinical Trials by Indication (Number of Drugs), 2023 - 2024
Figure 4-4: Global - Anti TIGIT Antibodies Clinical Trials by Patient Segment (Number of Drugs), 2023 - 2024
Figure 4-5: Global - Anti TIGIT Antibodies Clinical Trials by Phase (Number of Drugs), 2023 - 2024
Figure 6-1: Global - Cancer Incidences and Deaths (Million), 2020 and 2025
Figure 6-2: TIGIT Inhibitor Market Drivers
Figure 6-3: Stages of Drug Development
